Skip to main content
Erschienen in: Supportive Care in Cancer 7/2007

01.07.2007 | Original Article

The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial

verfasst von: Elizabeth L. Strevel, Colin Newman, Gregory R. Pond, Martha MacLean, Lillian L. Siu

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

The quality of informed consent in phase I trials is controversial, partially due to gaps in patient understanding. We assessed an educational DVD’s impact on knowledge and satisfaction in cancer patients newly referred to a phase I clinic.

Materials and methods

Forty-nine patients were randomly assigned to view an educational DVD (n = 22) which explained phase I trials or a placebo DVD (n = 27). Patients completed a questionnaire assessing knowledge of phase I studies and satisfaction with the DVD. The blinded interviewing physician (n = 8) rated the patient’s understanding of phase I trials.

Main results

The mean patient age was 56; 61% were male. Patients who viewed the educational DVD were less likely to believe that phase I trials determine drug efficacy (p = 0.019), more likely to know that phase I drugs have not been thoroughly studied in humans (p = 0.003), and less likely to believe that these agents have proven activity against human cancers (p = 0.008). More patients who viewed the educational DVD agreed/strongly agreed that the DVD provided useful information (p < 0.001), were confident in their knowledge of phase I trials (p = 0.031), felt aided in their decision to enter a phase I study (p = 0.011), and would have more questions for their physicians because of the DVD (p = 0.017). No statistically significant difference in physician perception of patient understanding or phase I trial accrual was observed between the educational and placebo DVD groups.

Conclusions

An educational DVD increased patient knowledge and satisfaction regarding participation in phase I clinical trials.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Agrawal M, Emanuel EJ (2003) Ethics of phase I oncology studies: Reexamining the arguments and data. JAMA 290:1075–1082PubMedCrossRef Agrawal M, Emanuel EJ (2003) Ethics of phase I oncology studies: Reexamining the arguments and data. JAMA 290:1075–1082PubMedCrossRef
2.
Zurück zum Zitat Bain NS, Campbell NC, Ritchie LD et al (2002) Striking the right balance in colorectal cancer care—a qualitative study of rural and urban patients. Fam Pract 19:369–374PubMedCrossRef Bain NS, Campbell NC, Ritchie LD et al (2002) Striking the right balance in colorectal cancer care—a qualitative study of rural and urban patients. Fam Pract 19:369–374PubMedCrossRef
3.
Zurück zum Zitat Cheng JD, Hitt J, Koczwara B et al (2000) Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 18:421–428PubMed Cheng JD, Hitt J, Koczwara B et al (2000) Impact of quality of life on patient expectations regarding phase I clinical trials. J Clin Oncol 18:421–428PubMed
4.
Zurück zum Zitat Daugherty CK, Banik DM, Janish L et al (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview study of 144 advanced cancer patients. IRB 22:6–14PubMedCrossRef Daugherty CK, Banik DM, Janish L et al (2000) Quantitative analysis of ethical issues in phase I trials: a survey interview study of 144 advanced cancer patients. IRB 22:6–14PubMedCrossRef
5.
Zurück zum Zitat Daugherty C, Ratain MJ, Grochowski E et al (1995) Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13:1062–1072PubMed Daugherty C, Ratain MJ, Grochowski E et al (1995) Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol 13:1062–1072PubMed
6.
Zurück zum Zitat Decoster G, Stein G, Holdener EE (1990) Responses and toxic deaths in phase I clinical trials. Ann Oncol 1:145–181 Decoster G, Stein G, Holdener EE (1990) Responses and toxic deaths in phase I clinical trials. Ann Oncol 1:145–181
7.
Zurück zum Zitat Eisenhauer EA, O’Dwyer PJ, Christian M et al (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684–692PubMed Eisenhauer EA, O’Dwyer PJ, Christian M et al (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684–692PubMed
8.
Zurück zum Zitat Emanuel EJ (1995) A phase I trial on the ethics of phase I trials. J Clin Oncol 13:1049–1051PubMed Emanuel EJ (1995) A phase I trial on the ethics of phase I trials. J Clin Oncol 13:1049–1051PubMed
9.
Zurück zum Zitat Faden RR, Beauchamp TL, King NMP (1986) A history and theory of informed consent. Oxford University Press, New York, NY Faden RR, Beauchamp TL, King NMP (1986) A history and theory of informed consent. Oxford University Press, New York, NY
10.
Zurück zum Zitat Flory J, Emanuel E (2004) Interventions to improve research participants’ understanding in informed consent for research: a systematic review. JAMA 292:1593–1601PubMedCrossRef Flory J, Emanuel E (2004) Interventions to improve research participants’ understanding in informed consent for research: a systematic review. JAMA 292:1593–1601PubMedCrossRef
11.
Zurück zum Zitat Fureman I, Meyers K, McLellan AT et al (1997) Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV efficacy trials. AIDS Educ Prev 9:330–341PubMed Fureman I, Meyers K, McLellan AT et al (1997) Evaluation of a video-supplement to informed consent: injection drug users and preventive HIV efficacy trials. AIDS Educ Prev 9:330–341PubMed
12.
Zurück zum Zitat Hlubocky FJ, Kass NE, Fogarty LA et al (2004) Effects of a CD-ROM educational intervention (CD) on prognosis understanding among advanced cancer patients (acp) enrolling in early phase clinical trials. Proc Am Soc Clin Oncol 22:532s (Abstract 6054) Hlubocky FJ, Kass NE, Fogarty LA et al (2004) Effects of a CD-ROM educational intervention (CD) on prognosis understanding among advanced cancer patients (acp) enrolling in early phase clinical trials. Proc Am Soc Clin Oncol 22:532s (Abstract 6054)
13.
Zurück zum Zitat Horstmann E, McCabe MS, Grochow L et al (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895–904PubMedCrossRef Horstmann E, McCabe MS, Grochow L et al (2005) Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 352:895–904PubMedCrossRef
14.
Zurück zum Zitat Hutchison C (1998) Phase I trials in cancer patients: participants’ perceptions. Eur J Cancer Care 7:15–22CrossRef Hutchison C (1998) Phase I trials in cancer patients: participants’ perceptions. Eur J Cancer Care 7:15–22CrossRef
15.
Zurück zum Zitat Hutchison C, Campbell S (2002) Evaluation of an information booklet for patients considering participation in phase I clinical trials in cancer. Eur J Cancer Care 11:131–138CrossRef Hutchison C, Campbell S (2002) Evaluation of an information booklet for patients considering participation in phase I clinical trials in cancer. Eur J Cancer Care 11:131–138CrossRef
16.
Zurück zum Zitat Itoh K, Sasaki Y, Fujii H et al (1997) Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Br J Cancer 76:107–113PubMed Itoh K, Sasaki Y, Fujii H et al (1997) Patients in phase I trials of anti-cancer agents in Japan: motivation, comprehension and expectations. Br J Cancer 76:107–113PubMed
17.
Zurück zum Zitat Itoh K, Sasaki Y, Miyata Y et al (1994) Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol 4:451–454 Itoh K, Sasaki Y, Miyata Y et al (1994) Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan. Cancer Chemother Pharmacol 4:451–454
18.
Zurück zum Zitat Joffe S, Miller FG (2006) Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 24:2987–2990PubMedCrossRef Joffe S, Miller FG (2006) Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol 24:2987–2990PubMedCrossRef
19.
Zurück zum Zitat Meade CD (1999) Improving understanding of the informed consent process and document. Sem Oncol Nurs 15:124–137CrossRef Meade CD (1999) Improving understanding of the informed consent process and document. Sem Oncol Nurs 15:124–137CrossRef
20.
Zurück zum Zitat Meropol NJ, Weinfurt KP, Burnett CB et al (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596PubMedCrossRef Meropol NJ, Weinfurt KP, Burnett CB et al (2003) Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician–patient communication. J Clin Oncol 21:2589–2596PubMedCrossRef
21.
Zurück zum Zitat Nitschke R (2004) Physician–patient communication in phase I cancer trials. J Clin Oncol 22:571–572PubMedCrossRef Nitschke R (2004) Physician–patient communication in phase I cancer trials. J Clin Oncol 22:571–572PubMedCrossRef
22.
Zurück zum Zitat Nurgat ZA, Craig W, Campbell NC et al (2005) Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer 92:1001–1005PubMedCrossRef Nurgat ZA, Craig W, Campbell NC et al (2005) Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy. Br J Cancer 92:1001–1005PubMedCrossRef
23.
Zurück zum Zitat Penman DT, Holland JC, Bahna GF et al (1984) Informed consent for investigational chemotherapy: patients’ and physicians’ perceptions. J Clin Oncol 2:849–855PubMed Penman DT, Holland JC, Bahna GF et al (1984) Informed consent for investigational chemotherapy: patients’ and physicians’ perceptions. J Clin Oncol 2:849–855PubMed
24.
Zurück zum Zitat Rajagopal S, Goodman PJ, Tannock IF (1994) Adjuvant chemotherapy for breast cancer: discordance between physicians’ perception of benefit and the results of clinical trials. J Clin Oncol 12:1296–1304PubMed Rajagopal S, Goodman PJ, Tannock IF (1994) Adjuvant chemotherapy for breast cancer: discordance between physicians’ perception of benefit and the results of clinical trials. J Clin Oncol 12:1296–1304PubMed
25.
Zurück zum Zitat Roberts Jr TG, Goulart BH, Squitieri L et al (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130–2140PubMedCrossRef Roberts Jr TG, Goulart BH, Squitieri L et al (2004) Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292:2130–2140PubMedCrossRef
26.
Zurück zum Zitat Rodenhuis S, van den Heuvel WJA, Annyas AA et al (1984) Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol 20:457–462PubMedCrossRef Rodenhuis S, van den Heuvel WJA, Annyas AA et al (1984) Patient motivation and informed consent in a phase I study of an anticancer agent. Eur J Cancer Clin Oncol 20:457–462PubMedCrossRef
27.
Zurück zum Zitat Rossi M, McClellan R, Chou L et al (2004) Informed consent for ankle fracture surgery: patient comprehension of verbal and videotaped information. Foot Ankle Int 25:756–762PubMed Rossi M, McClellan R, Chou L et al (2004) Informed consent for ankle fracture surgery: patient comprehension of verbal and videotaped information. Foot Ankle Int 25:756–762PubMed
28.
Zurück zum Zitat Von Hoff DD, Turner J (1991) Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115–122 Von Hoff DD, Turner J (1991) Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9:115–122
29.
Zurück zum Zitat Weeks JC, Cook EF, O’Day SJ et al (1998) Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 279:1709–1714PubMedCrossRef Weeks JC, Cook EF, O’Day SJ et al (1998) Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 279:1709–1714PubMedCrossRef
30.
Zurück zum Zitat Weinfurt KP, Castel LD, Li Y et al (2003) The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98:166–175PubMedCrossRef Weinfurt KP, Castel LD, Li Y et al (2003) The correlation between patient characteristics and expectations of benefit from phase I clinical trials. Cancer 98:166–175PubMedCrossRef
31.
Zurück zum Zitat Weston J, Hannah M, Downes J (1997) Evaluating the benefits of a patient information video during the informed consent process. Patient Educ Couns 30:239–245PubMedCrossRef Weston J, Hannah M, Downes J (1997) Evaluating the benefits of a patient information video during the informed consent process. Patient Educ Couns 30:239–245PubMedCrossRef
32.
Zurück zum Zitat Wirshing DA, Sergi MJ, Mintz J (2005) A videotape intervention to enhance the informed consent process for medical and psychiatric treatment research. Am J Psychiatr 162:186–188PubMedCrossRef Wirshing DA, Sergi MJ, Mintz J (2005) A videotape intervention to enhance the informed consent process for medical and psychiatric treatment research. Am J Psychiatr 162:186–188PubMedCrossRef
33.
Zurück zum Zitat Yoder LH, O’Rourke TJ, Etnyre A et al (1997) Expectations and experiences of patients with cancer participating in phase I clinical trials. Oncol Nurs Forum 24:891–896PubMed Yoder LH, O’Rourke TJ, Etnyre A et al (1997) Expectations and experiences of patients with cancer participating in phase I clinical trials. Oncol Nurs Forum 24:891–896PubMed
Metadaten
Titel
The impact of an educational DVD on cancer patients considering participation in a phase I clinical trial
verfasst von
Elizabeth L. Strevel
Colin Newman
Gregory R. Pond
Martha MacLean
Lillian L. Siu
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2007
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-006-0199-2

Weitere Artikel der Ausgabe 7/2007

Supportive Care in Cancer 7/2007 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.